Tran Christian, Kasraee Behrooz, Grand Denise, Carraux Pierre, Didierjean Liliane, Sorg Olivier, Saurat Jean-Hilaire
Department of Dermatology, University Hospital, Geneva, Switzerland.
Dermatology. 2005;210 Suppl 1:6-13. doi: 10.1159/000082542.
Retinoids and alpha-hydroxy acids (AHAs) are major compounds in topical therapy. They exert distinct but potentially complementary activities. However, their association is limited by their respective irritating potential. Recently, the first association between a retinoid and an AHA has been achieved; this formulation (RALGA) associates retinaldehyde (RAL)--a precursor of retinoic acid (RA)--and glycolic acid (GA)--an AHA.
To study the pharmacological properties of RALGA.
The bioavailability of RAL into the skin after topical RALGA was studied by HPLC, and its bioconversion to RA was analysed by measuring the enzyme activity of retinaldehyde dehydrogenase and the RA content in the epidermis and dermis. The retinoid activity of RALGA was studied on the modulation of Hhb4 keratin mRNA on the tail of C57BL/6 mice, and its comedolytic properties on the size and density of dermal cysts and the morphology of sebaceous glands in hairless mice.
Epidermal and dermal concentrations of RAL and RA were higher after RALGA treatment, as compared to both RAL 0.1% alone and RA 0.05% alone; this indicates that the presence of GA favours the bioavailability and biotransformation of RAL into RA. The retinoid activity of RALGA (suppression of Hhb4 mRNA keratin) was similar to that of RAL alone, indicating that the presence of GA does not interfere with specific retinoid activity; GA alone had no effect in this test, which confirms the specificity of Hhb4 mRNA keratin modulation for retinoid activity. The diameter and the density of dermal cysts as well as the size of sebaceous glands were significantly decreased by RALGA.
These observations indicate that the addition of an AHA such as GA to a retinoid such as RAL results in a better bioavailability of the retinoid, thus a higher delivery of RA, which potentiates the biological activities of the retinoid. This combination allows a delivery of high amounts of RA in the skin while preventing the side-effects usually observed with high concentrations of topical RA.
维甲酸和α - 羟基酸(AHA)是局部治疗中的主要化合物。它们具有不同但可能互补的活性。然而,它们的联合应用受到各自潜在刺激性的限制。最近,首次实现了维甲酸与AHA的联合;这种配方(RALGA)将视黄醛(RAL)——维甲酸(RA)的前体——与乙醇酸(GA)——一种AHA联合。
研究RALGA的药理学特性。
通过高效液相色谱法研究局部应用RALGA后RAL在皮肤中的生物利用度,并通过测量视黄醛脱氢酶的酶活性以及表皮和真皮中RA的含量来分析其向RA的生物转化。在C57BL/6小鼠尾部研究RALGA对视黄醛活性的影响,观察其对Hhb4角蛋白mRNA的调节作用,并在无毛小鼠中研究其对真皮囊肿大小和密度以及皮脂腺形态的溶粉刺特性。
与单独使用0.1%的RAL和单独使用0.05%的RA相比,RALGA治疗后表皮和真皮中RAL和RA的浓度更高;这表明GA的存在有利于RAL的生物利用度及其向RA的生物转化。RALGA的视黄醛活性(抑制Hhb4 mRNA角蛋白)与单独使用RAL相似,表明GA的存在不干扰特定的视黄醛活性;单独使用GA在该试验中无作用,这证实了Hhb4 mRNA角蛋白调节对视黄醛活性的特异性。RALGA可使真皮囊肿的直径和密度以及皮脂腺的大小显著减小。
这些观察结果表明,在维甲酸如RAL中添加AHA如GA可提高维甲酸的生物利用度,从而提高RA的递送量,增强维甲酸的生物学活性。这种组合能够在皮肤中递送大量的RA,同时防止通常在高浓度局部应用RA时观察到的副作用。